Zydus Lifesciences Gets Nomura's 'Buy' Upgrade On Earnings Growth, Currency Movement

Nomura has upgraded Zydus Lifesciences Ltd. to a 'buy' from its earlier 'neutral' stance, raising the target price to Rs 1,140 from Rs 1,030, implying a potential upside of 16%. Robust earnings growth, favourable currency movement, and strategic partnerships in the US market are key growth drivers, the brokerage said.

Share price of Zydus Lifesciences fell as much as 0.77% to Rs 1,002.75 apiece, the lowest level since Jan. 8, 2025. It pared loss to trade 0.07% higher at Rs 1,011.25 apiece, as of 9:33 a.m. This compares to a 0.04% decline in the NSE Nifty 50.

The stock has risen 43.05% in the last 12 months. The relative strength index was at 58.54.

Out of 33 analysts tracking the company, 17 maintain a 'buy' rating, 10 recommend a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 9%.